World News: 01:08 GMT Thursday 30th May 2019. [Hagens Berman Sobol Shapiro LLP via Globe Newswire via SPi World News]
SAN FRANCISCO, May 29, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, with nine offices in eight cities around the country and eighty attorneys, reminds investors in Apyx Medical Corporation () of the in the securities class action, No. 8:19-cv-00919, filed in the United States District Court for the Middle District of Florida.
If you purchased or otherwise acquired Apyx Medical securities (the “Class Period”) and suffered significant losses, you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case.
If you wish to serve as a lead plaintiff in this class action, you must move the Court no later than . Contact Hagens Berman immediately for more information about the case and being a lead plaintiff:
or contact Reed Kathrein, who is leading the firm’s investigation, by calling or emailing
According to the complaint, Defendants misstated and/or concealed that (1) Apyx’s J-Plasma clinical study for dermal resurfacing did not meet its primary efficacy endpoint, and (2) the study did not support the Company’s application to obtain regulators’ approval for such use.
“We’re focused on investors’ losses, certain matters flagged in a recent bearish analyst report, and whether investors may have been misled,” said Hagens Berman partner Reed Kathrein.
Globe Newswire: 01:08 GMT Thursday 30th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.